NCT03551821

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Aclaris Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).

Detailed description

This is an open-label study which will be conducted at 1 to 2 sites. Subjects will be required to have a clinical diagnosis of AA, AU or AT with unilateral or bilateral loss of eyebrow hair. Subjects will apply study medication to the entire affected eyebrow(s), twice-daily for 24 weeks. Safety and tolerability will be evaluated throughout the study. The duration of the study participation is anticipated to be a maximum of 233 days.

Conditions

• Alopecia Areata
• Alopecia Totalis
• Alopecia Universalis

Interventions

Type	Name	Description
DRUG	ATI-50002	Topical Solution

Timeline

• Start date: 2018-04-11
• Primary completion: 2018-11-06
• Completion: 2018-11-06
• First posted: 2018-06-11
• Last updated: 2019-12-11
• Results posted: 2019-12-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study